Translate this page into:
Essential Thrombocythemia Presenting as Paraneoplastic Glomerulonephritis
Address for correspondence: Prof. M. C. Abdulla, Department of General Medicine, M.E.S. Medical College, Perinthalmanna, Malappuram, Kerala, India. E-mail: drcamans@gmail.com
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
This article was originally published by Medknow Publications & Media Pvt Ltd and was migrated to Scientific Scholar after the change of Publisher.
Dear Sir,
A 44-year-old male was admitted with reduced urinary output and bilateral pedal edema for 1 week. He had bipolar affective disorder for the last 14 years but was not receiving any medications. Examination showed facial puffiness, bilateral pedal edema, and moderate splenomegaly. Hemoglobin was 11.3 g/dl (normocytic, normochromic), total white blood cell count 23,600/μl, platelet count 7.5 × 109/L, and erythrocyte sedimentation rate 68 mm in 1 h. Peripheral smear showed normocytic normochromic red blood cells with mild leukocytosis and thrombocytosis. He had nephrotic range proteinuria, hypoalbuminemia, and moderate renal failure. Renal biopsy revealed focal segmental glomerulosclerosis [Figure 1 lower panel]. Bone marrow biopsy showed a cellular marrow with megakaryocyte hyperplasia and areas of megakaryocyte dyspoiesis [Figure 1 upper panel]. HIV, hepatitis B, and hepatitis C serologies were negative. Antinuclear antibody was negative. The Janus kinase 2 gene (JAK2) V617F mutation was positive, but BCR/ABL fusion gene was negative. He was diagnosed to have essential thrombocythemia with paraneoplastic focal segmental glomerulosclerosis and was treated with high-dose steroids, hemodialysis, and hydroxyurea. His renal failure stabilized with treatment and he was continued on hydroxyurea.
Glomerular diseases are associated with many solid and hematologic malignancies. Paraneoplastic glomerular lesions are most likely due to abnormal products produced by tumor cells although the exact pathogenesis is unclear. The treatment of these cancer-associated glomerulopathies is primarily targeted at treating the underlying malignancy.
Myeloproliferative disorders include chronic myelogenous leukemia, polycythemia Vera (PCV), and essential thrombocythemia. Among the myeloproliferative neoplasms, PCV, essential thrombocythemia, and primary myelofibrosis are associated with focal segmental glomerulosclerosis. Glomerular disorders associated with myeloproliferative disorders are usually late complications and tend to have a poor renal prognosis. Failure to recognize paraneoplastic glomerulonephritis can lead to undue delay in initiating anticancer medications.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.